Bayer's Critical Fortnight: A Legal Cliffhanger and a Pipeline Catalyst

Bayer faces a defining fortnight with a key Supreme Court glyphosate hearing, promising stroke drug data, and Q1 results, as it navigates legal risks and financial pressures.

Investors in Bayer are bracing for a fortnight packed with events that could define the company's trajectory for years. The coming days feature a shareholder meeting, a landmark Supreme Court hearing, and the imminent release of pivotal quarterly results, all against the backdrop of promising new clinical data for a key pipeline drug.

The catalyst for renewed optimism arrived over the weekend with the full publication of the OCEANIC-STROKE trial in the New England Journal of Medicine. The Phase III study, involving over 12,000 patients, demonstrated that Bayer's experimental drug asundexian reduced ischemic strokes by 26% compared to a placebo, without increasing bleeding risk. The U.S. Food and Drug Administration has already granted the therapy Fast-Track designation, though it remains unapproved globally. This data is seen as crucial for filling the revenue gap expected from the patent expiry of the blockbuster blood thinner Xarelto.

Financially, the company is navigating turbulent waters. For the full year 2025, Bayer reported sales of 45.6 billion euros, with EBITDA falling to 9.7 billion euros. The net loss reached 3.6 billion euros, heavily impacted by provisions for ongoing litigation. Free cash flow contracted by nearly one-third. Looking ahead, management is targeting sales between 45 and 47 billion euros for 2026, with an EBITDA forecast of 9.6 to 10.1 billion euros. The company anticipates a negative free cash flow for the current year.

The most significant near-term event is scheduled for April 27, when the U.S. Supreme Court begins oral arguments in the pivotal glyphosate case, Durnell v. Monsanto. The core legal question is whether federal law preempts state-level liability claims against the company. A favorable ruling could shield Bayer from tens of thousands of pending lawsuits. Since acquiring Monsanto, the group has paid out more than $11 billion in settlements and judgments, with over 100,000 claims still outstanding. A separate class-action settlement worth $7.25 billion also awaits final approval. DZ Bank analyst Peter Spengler views a positive Supreme Court outcome as key to making the company's legal risks more calculable.

Preceding that hearing, Bayer will hold its virtual Annual General Meeting on April 24. The board proposes an unchanged dividend of 0.11 euros per share for the past fiscal year, with the ex-dividend date set for the following Monday. The meeting will also see a board reshuffle, with Marcel Smits and Alfred Stern nominated to replace longstanding members Paul Achleitner and Colleen Goggins.

Following the AGM, Bayer enters a quiet period on Monday, halting the release of market-sensitive data until first-quarter results are published on May 12. The market will scrutinize those figures for evidence that cost-cutting measures are taking hold and that the agricultural business is providing stable support.

Analyst opinions reflect the company's complex crosscurrents. Deutsche Bank Research recently raised its price target to 43 euros but maintains a "Hold" rating. In contrast, UBS reaffirmed a "Buy" recommendation with a 52-euro target, with analyst Matthew Weston highlighting the growth dynamics of newer pharmaceutical products Nubeqa and Kerendia.

On the Frankfurt exchange, Bayer shares closed at 41.10 euros, marking a gain of roughly 8% since the start of the year. Over a twelve-month period, the stock has surged nearly 96%, though it remains about 16% below its 52-week high of 49.17 euros.

Longer-term, management is guiding for a return to mid-single-digit sales growth from 2027 onwards, with the ambition to lift the operating margin to around 30% by the end of the decade. The company has stated that potential U.S. import tariffs on pharmaceuticals are already factored into its financial planning. The coming weeks will test the resilience of that roadmap.